144 related articles for article (PubMed ID: 32154172)
1. Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease.
Bruera G; Ricevuto E
Front Oncol; 2020; 10():172. PubMed ID: 32154172
[No Abstract] [Full Text] [Related]
2. Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in
Bruera G; Massacese S; Pepe F; Malapelle U; Dal Mas A; Ciacco E; Calvisi G; Troncone G; Simmaco M; Ricevuto E
Ther Adv Med Oncol; 2019; 11():1758835919846421. PubMed ID: 31205502
[TBL] [Abstract][Full Text] [Related]
3. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
Bruera G; Santomaggio A; Cannita K; Baldi PL; Tudini M; De Galitiis F; Mancini M; Marchetti P; Antonucci A; Ficorella C; Ricevuto E
BMC Cancer; 2010 Oct; 10():567. PubMed ID: 20958992
[TBL] [Abstract][Full Text] [Related]
4. Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice.
Bruera G; Pepe F; Malapelle U; Di Staso M; Dal Mas A; Di Giacomo D; Scerbo G; Santilli M; Ciacco E; Simmaco M; Troncone G; Coco C; Giuliante F; Ricevuto E
Ann Transl Med; 2021 Jun; 9(12):1027. PubMed ID: 34277827
[TBL] [Abstract][Full Text] [Related]
5. Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy.
Bruera G; Russo A; Galvano A; Rizzo S; Ricevuto E
Oncotarget; 2017 Jun; 8(23):37875-37883. PubMed ID: 28053287
[TBL] [Abstract][Full Text] [Related]
6. Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study.
Bruera G; Massacese S; Candria S; Galvano A; Manetta R; Giordano AV; Carducci S; Di Sibio A; Ciacco E; Russo A; Ricevuto E;
Oncotarget; 2018 Aug; 9(61):31861-31876. PubMed ID: 30159128
[TBL] [Abstract][Full Text] [Related]
7. Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With
Bruera G; D'Andrilli A; Simmaco M; Guadagni S; Rendina EA; Ricevuto E
Front Oncol; 2020; 10():1155. PubMed ID: 32850329
[No Abstract] [Full Text] [Related]
8. Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients.
Bruera G; Cannita K; Giordano AV; Vicentini R; Ficorella C; Ricevuto E
Biomed Res Int; 2013; 2013():143273. PubMed ID: 24307987
[TBL] [Abstract][Full Text] [Related]
9. Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice.
Bruera G; Giuliani A; Romano L; Chiominto A; Di Sibio A; Mastropietro S; Cosenza P; Ricevuto E; Schietroma M; Carlei F;
BMC Cancer; 2019 Oct; 19(1):960. PubMed ID: 31619203
[TBL] [Abstract][Full Text] [Related]
10. Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer.
Bruera G; Massacese S; Galvano A; Mas AD; Guadagni S; Calvisi G; Ciacco E; Russo A; Ricevuto E;
Oncotarget; 2018 Apr; 9(29):20339-20350. PubMed ID: 29755655
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
Bruera G; Cannita K; Giuliante F; Lanfiuti Baldi P; Vicentini R; Marchetti P; Nuzzo G; Antonucci A; Ficorella C; Ricevuto E
Clin Colorectal Cancer; 2012 Jun; 11(2):119-26. PubMed ID: 22206922
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments.
Bruera G; Ricevuto E;
Pharmgenomics Pers Med; 2020; 13():601-617. PubMed ID: 33235483
[TBL] [Abstract][Full Text] [Related]
13.
Bruera G; Pepe F; Malapelle U; Pisapia P; Mas AD; Di Giacomo D; Calvisi G; Troncone G; Ricevuto E
Oncotarget; 2018 May; 9(41):26279-26290. PubMed ID: 29899858
[TBL] [Abstract][Full Text] [Related]
14. Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.
Cortellini A; Cannita K; Parisi A; Lanfiuti Baldi P; Venditti O; D'Orazio C; Dal Mas A; Calvisi G; Giordano AV; Vicentini V; Vicentini R; Felicioni L; Marchetti A; Buttitta F; Russo A; Ficorella C
Onco Targets Ther; 2019; 12():2159-2170. PubMed ID: 30988620
[TBL] [Abstract][Full Text] [Related]
15. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
16. The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?
Bruera G; Cannita K; Tessitore A; Russo A; Alesse E; Ficorella C; Ricevuto E
Crit Rev Oncol Hematol; 2015 Mar; 93(3):190-202. PubMed ID: 25459669
[TBL] [Abstract][Full Text] [Related]
17. Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice.
Ficorella C; Bruera G; Cannita K; Porzio G; Baldi PL; Tinari N; Natoli C; Ricevuto E
Clin Colorectal Cancer; 2012 Dec; 11(4):229-37. PubMed ID: 22694897
[TBL] [Abstract][Full Text] [Related]
18. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Park SR; Hong YS; Lim HS; Seong MW; Kong SY; Kim SY; Park YI; Jung KH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):953-64. PubMed ID: 23982118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
